|
|
Volumn 21, Issue 10 Suppl, 2003, Pages
|
|
Biologic and immunologic therapies for ovarian cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
BIOLOGICAL PRODUCT;
CA 125 ANTIGEN;
CA 15-3 ANTIGEN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
GAMMA INTERFERON;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY HMFG1;
OREGOVOMAB;
PROTEIN P53;
RADIOPHARMACEUTICAL AGENT;
TP53 PROTEIN, HUMAN;
TRASTUZUMAB;
YTTRIUM;
ANIMAL;
FEMALE;
GENE THERAPY;
GENETICS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MULTIMODALITY CANCER THERAPY;
OVARY TUMOR;
RECURRENT DISEASE;
REVIEW;
TREATMENT OUTCOME;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL PRODUCTS;
CA-125 ANTIGEN;
CA-15-3 ANTIGEN;
COMBINED MODALITY THERAPY;
FEMALE;
GENE THERAPY;
HUMANS;
IMMUNOTHERAPY;
INTERFERON TYPE II;
INTERFERON-ALPHA;
OVARIAN NEOPLASMS;
RADIOPHARMACEUTICALS;
RECEPTOR, ERBB-2;
RECURRENCE;
TREATMENT OUTCOME;
TUMOR SUPPRESSOR PROTEIN P53;
YTTRIUM ISOTOPES;
MLCS;
MLOWN;
|
|
EID: 1242334764
PISSN: None
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/jco.2003.01.517 Document Type: Review |
|
Times cited : (63)
|
|
References (44)
|
